文献速递神经MR

联合宏观与微观影像组学模型用于年轻高危低级别胶质瘤放化疗决策的研究

Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model.
PubMed 文献 · Eur Radiol · 2023-10-27

本研究构建了联合宏观MRI与微观病理图像的多模态融合影像组学(MFR)模型,用于预测年轻高危低级别胶质瘤(HRLGGs)术后替莫唑胺(TMZ)化疗敏感性。模型预测AUC为0.950(95%CI: 0.942-0.958),敏感度0.833(95%CI: 0.780-0.848),特异度0.929(95%CI: 0.914-0.936),且预测效能显著高于已报道的分子标志物(p<0.001),并可作为无进展生存期(PFS)的预测因子。

要点

  • MFR模型联合宏观MRI与微观病理图像预测HRLGGs对TMZ的化疗敏感性,AUC达0.950。
  • 肿瘤宏观纹理复杂度和微观核大小在敏感组与不敏感组间差异有统计学意义(p<0.001)。
  • MFR预测效能显著高于已报道的分子标志物(p<0.001),并可预测PFS。

核心结论

  • 包含影像组学与病理特征的MFR模型能准确预测HRLGGs术后TMZ治疗反应,可识别最可能从术后 upfront TMZ治疗中获益的患者。

研究设计与样本

  • 研究提出联合宏观MRI与微观病理图像的多模态融合影像组学(MFR)模型,通过注意力机制自适应整合多尺度特征,以客观缓解率和无进展生存期(PFS)为指标预测TMZ化疗敏感性。

关键影像表现/征象

  • 宏观肿瘤纹理复杂度与微观核大小在化疗敏感组与不敏感组之间差异有统计学意义(p<0.001)。

诊断标准与关键数值

  • MFR模型预测化疗敏感性的AUC为0.950(95%CI: 0.942-0.958)。
  • MFR模型敏感度为0.833(95%CI: 0.780-0.848),特异度为0.929(95%CI: 0.914-0.936)。
  • MFR模型阳性预测值为0.833(95%CI: 0.811-0.860),阴性预测值为0.929(95%CI: 0.914-0.934)。
  • MFR模型预测效能显著高于已报道的分子标志物(p<0.001)。

临床应用与阅片要点

  • MFR模型可辅助识别最可能从术后 upfront TMZ治疗中获益的年轻高危低级别胶质瘤患者。
  • 宏观肿瘤纹理复杂度与微观核大小可作为与化疗敏感性相关的影像标志物。
  • MFR模型同时可作为PFS的预测因子。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: As a few types of glioma, young high-risk low-grade gliomas (HRLGGs) have higher requirements for postoperative quality of life. Although adjuvant chemotherapy with delayed radiotherapy is the first treatment strategy for HRLGGs, not all HRLGGs benefit from it. Accurate assessment of chemosensitivity in HRLGGs is vital for making treatment choices. This study developed a multimodal fusion radiomics (MFR) model to support radiochemotherapy decision-making for HRLGGs.

METHODS: A MFR model combining macroscopic MRI and microscopic pathological images was proposed. Multiscale features including macroscopic tumor structure and microscopic histological layer and nuclear information were grabbed by unique paradigm, respectively. Then, these features were adaptively incorporated into the MFR model through attention mechanism to predict the chemosensitivity of temozolomide (TMZ) by means of objective response rate and progression free survival (PFS).

RESULTS: Macroscopic tumor texture complexity and microscopic nuclear size showed significant statistical differences (p < 0.001) between sensitivity and insensitivity groups. The MFR model achieved stable prediction results, with an area under the curve of 0.950 (95% CI: 0.942-0.958), sensitivity of 0.833 (95% CI: 0.780-0.848), specificity of 0.929 (95% CI: 0.914-0.936), positive predictive value of 0.833 (95% CI: 0.811-0.860), and negative predictive value of 0.929 (95% CI: 0.914-0.934). The predictive efficacy of MFR was significantly higher than that of the reported molecular markers (p < 0.001). MFR was also demonstrated to be a predictor of PFS.

CONCLUSIONS: A MFR model including radiomics and pathological features predicts accurately the response postoperative TMZ treatment.

CLINICAL RELEVANCE STATEMENT: Our MFR model could identify young high-risk low-grade glioma patients who can have the most benefit from postoperative upfront temozolomide (TMZ) treatment.

KEY POINTS: • Multimodal radiomics is proposed to support the radiochemotherapy of glioma. • Some macro and micro image markers related to tumor chemotherapy sensitivity are revealed. • The proposed model surpasses reported molecular markers, with a promising area under the curve (AUC) of 0.95.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wu G, Shi Z, Li Z, et al. Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model. Eur Radiol. 2023. PMID: 37889272. doi:10.1007/s00330-023-10378-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。